IP Library Granted Patent US 9,914,729
Granted Patent B2
US 9,914,729 · App. 15/229,561 · Granted Mar 13, 2018

Amides of acetic and propionic acids

Inventors: Joachim Luithle (Wulfrath, DE); Frank-Gerhard BÖβ (Sunninghill, GB); Christina Erb (Wiesbaden, DE); Katrin Schnizler (Rodenbach, DE); Timo Flessner (Wuppertal, DE); Marja van Kampen (Neu-Isenburg, DE); Christoph Methfessel (Wuppertal, DE)
Assignee: BAYER INTELLECTUAL PROPERTY GMBH
C07D453/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,729
App. No.
15/229,561
Granted
Mar 13, 2018
Kind
B2
Abstract

The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.

Claims (24)

1. A compound selected from the group consisting of:

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride, and

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride.

2. The compound of claim 1 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride.

3. The compound of claim 1 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride.

4. The compound of claim 1 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride.

5. The compound of claim 1 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride.

6. The compound of claim 1 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride.

7. A pharmaceutical composition comprising:

i) a compound selected from the group consisting of:

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride;

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride, and

2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride; and

ii) one or more pharmaceutically acceptable carriers or excipients.

8. The pharmaceutical composition of claim 7 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride.

9. The pharmaceutical composition of claim 7 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride.

10. The pharmaceutical composition of claim 7 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride.

11. The pharmaceutical composition of claim 7 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride.

12. The pharmaceutical composition of claim 7 , wherein the compound is 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: LUITHLE, JOACHIM; BÖSS, FRANK-GERHARD; ERB, CHRISTINA; SCHNIZLER, KATRIN; FLESSNER, TIMO; VAN KAMPEN, MARJA; METHFESSEL, CHRISTOPH
To: BAYER HEALTHCARE AG
Reel/Frame 043727/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 043727/0538 →
CHANGE OF NAME Recorded Sep 28, 2017
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 044047/0767 →
MERGER Recorded Sep 28, 2017
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 044047/0879 →
Priority Claims (1)
DE 102 11 416 · Mar 15, 2002 · national
Continuity (5)
Continuation 14633985 · Feb 27, 2015
Continuation 13968536 · Aug 16, 2013
Continuation 12494009 · Jun 29, 2009
Continuation 10508106
Related Publication 20170183339A1 · Jun 29, 2017